ripekg:evaluation/RIPEACF96EE4CD6A96F4B |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:evidence-aggregation/RIPEACF96EE4CD6A96F4B |
tido:contributesTo |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:integrity-assessment-hypothesis/RIPEACF96EE4CD6A96F4B-human-1-1 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:integrity-assessment-hypothesis/RIPEACF96EE4CD6A96F4B-human-1-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:integrity-assessment-hypothesis/RIPEACF96EE4CD6A96F4B-human-1-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:integrity-assessment-hypothesis/RIPEACF96EE4CD6A96F4B-human-2-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:integrity-assessment-hypothesis/RIPEACF96EE4CD6A96F4B-human-overall |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:integrity-assessment-hypothesis/RIPEACF96EE4CD6A96F4B-inspectai-1-1 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:integrity-assessment-hypothesis/RIPEACF96EE4CD6A96F4B-inspectai-1-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:integrity-assessment-hypothesis/RIPEACF96EE4CD6A96F4B-inspectai-1-3 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:integrity-assessment-hypothesis/RIPEACF96EE4CD6A96F4B-inspectai-2-2 |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:publication-details/RIPEACF96EE4CD6A96F4BEffect of saffron supplementation on Parkinson’s disease: a study protocol for a triple-blind randomised controlled clinical trial |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:registry-evidence/RIPEACF96EE4CD6A96F4B |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
rdf:type |
rdfs:Resource |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
rdf:type |
owl:Thing |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
rdf:type |
ripe:ResearchIntegrityAssessmentResearch integrity assessment |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
rdf:type |
tido:Case |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripe:assesses |
ripekg:work/10.1136%2Fbmjopen-2024-093167Effect of saffron supplementation on Parkinson’s disease: a study protocol for a triple-blind randomised controlled clinical trial |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripe:assesses |
ripekg:work/10.1136%2Fbmjopen-2024-093167Protected by copyright, including for uses related to text and data mining, AI training, and similar technologies |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:integrity-assessment-question/post-publication-notices/1.0.01.2. Does the study have an associated expression of concern or other relevant post-publication notice? |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:integrity-assessment-question/post-publication-notices/1.0.0post-publication notices |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.01.3. Do other studies by the research team highlight causes for concern? |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:integrity-assessment-question/research-team-related-concerns/1.0.0research-team-related concerns |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:integrity-assessment-question/retraction-status/1.0.01.1. Does the study have an associated retraction? |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:integrity-assessment-question/retraction-status/1.0.0retraction status |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:integrity-assessment-question/study-registration/1.0.02.2. Are there concerns relating to the timing or absence of study registration? |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:integrity-assessment-question/study-registration/1.0.0study registration |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:overall-integrity-assessment-question/1.0.0What is the overall integrity assessment of the study? |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
tido:investigates |
ripekg:overall-integrity-assessment-question/1.0.0overall integrity assessment |
ripekg:retraction-notice/28473Clinical trial of the effects of coenzyme Q10 supplementation on glycemic control and markers of lipid profiles in diabetic hemodialysis patients |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |
ripekg:study-design-evidence/RIPEACF96EE4CD6A96F4B |
prov:wasMemberOf |
ripekg:research-integrity-assessment/RIPEACF96EE4CD6A96F4B |